Clinical Trials Browser

Phase 1 × sparsentan × 30 days × Clear all

NCT07224776 2026-05-18

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Phase 1 Not yet recruiting

Neoplasms, Proteinuria